Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Neurology(R) Neuroimmunology & Neuroinflammation|January 24, 2023
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-StudyMartin W Hümmert, Franziska Bütow, Daria Tkachenko, et al.Neurology|July 2, 2026
Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort StudyDaniel Engels, Patrick Schindler, Joachim Havla, et al.Journal of Neurology|December 21, 2024
Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and visionMihaela Nicolescu, Vivien Häußler, Friedemann Paul, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 27, 2024
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGADVivien Häußler, Corinna Trebst, Daniel Engels, et al.Neurology|October 1, 2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European CohortMarius Ringelstein, Susanna Asseyer, Gero Lindenblatt, et al.Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.Neurology(R) Neuroimmunology & Neuroinflammation|November 17, 2021
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum DisordersMarius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, et al.Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.Pageof 3